Kalaris Therapeutics, Inc. (KLRS): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Kalaris Therapeutics, Inc. (KLRS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d125092dex101.htm EX-10.1 EX-10.1 EXHIBIT 10.1 Execution Version EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of July 7, 2026 by and between Kalaris Therapeutics, Inc. (the “Company”), and Liisa Bayko (the “Executive”) (together, the “Part
How this was made
The 30-second read
Why it matters
This is primarily governance and compensation disclosure. It may modestly affect expectations around finance leadership, but it does not provide new business metrics or forward-looking guidance in the provided text.
Market read
For KLRS, the actionable takeaway is the confirmed CFO appointment and disclosed compensation structure, not a new financial forecast.
What to watch
Traders may be over-weighting the compensation details (salary, option size) without knowing the executive’s prior track record or whether there are concurrent internal accounting or financing issues not included in the excerpt.
Background
The SEC 8-K (Item 5.02) reports director/officer changes and includes an employment agreement for a newly appointed CFO.
Ticker impact
Kalaris Therapeutics appoints Liisa Bayko as Chief Financial Officer under a new employment agreement with $475,000 base salary and equity option.
Likely limited, with any move driven by broader sentiment rather than new fundamentals.
The filing is an 8-K executive/compensation item. It discloses role, start date, and pay terms, but does not include earnings, guidance, clinical, or deal specifics that would directly reprice the business.
Market effects
Minimal. CFO changes are generally company-specific unless tied to a strategic pivot, which is not disclosed here.
None indicated.
None indicated.
Counterpoint
The market may treat the CFO hire as a positive signal for financial reporting readiness, but the filing lacks any performance targets or turnaround narrative.
Key entities
- issuerKalaris Therapeutics, Inc.
Subject of the SEC 8-K, reporting the CFO appointment and related employment terms.
- executiveLiisa Bayko
Appointed Chief Financial Officer under an employment agreement effective July 20, 2026.
